FDA Grants Regenerative Medicine Designation to Humacyte Vascular Tissue Therapy

The FDA granted expedited review to Humacyte’s tissue therapy under the new Regenerative Medicine Advanced Therapy pathway — one of the first products to receive the designation established by the 21st Century Cures Act.
Source: Drug Industry Daily